NovaBay Pharmaceuticals (NBY) today published a comprehensive blog post on TheChairmansBlog.com addressing the issue of antimicrobial resistance. TheChairmansBlog.com is an exclusive, online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NovaBay’s Chairman and CEO, Dr. Ron Najafi, explains the history of bacteria and how they have grown resistant to antibiotics over time. The “Golden Age of Antibiotics” that led to the “Post-Antibiotic Era,” according to Dr. Najafi, “should not be surprising.” He provides information on NovaBay’s technology to address the issue of antimicrobial resistance. Read the full blog post from Ron Najafi on TheChairmansBlog.com (http://www.thechairmansblog.com/ron-najafi/2013-03/the-growing-crisis-of-antibiotic-resistance.html).
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide® compounds. Aganocides are novel, broad-spectrum, fast-acting, synthetic anti-infectives designed to mimic the body’s defense against infection. They are active against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.
TheChairmansBlog.com is an exclusive, online media publication where publically and privatively held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. In addition to management`s insightful blog posts, TheChairmansBlog.com staff and aggregate partners contribute articles on finance, technology, health, and energy while providing updated market trends, news, and information.